Phase 4
Completed N=148
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
Source: ClinicalTrials.gov NCT00536172 ↗Enrolled (actual)
148
Serious AEs
19.6%
Results posted
Feb 2014
Primary outcomePrimary: Depression as Assessed by the Quick Inventory of Depressive Symptomatology-Self Rated 16 (QIDS-SR-16) — 6; 16 participants
Summary
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Depression as Assessed by the Quick Inventory of Depressive Symptomatology-Self Rated 16 (QIDS-SR-16) |
6; 16 | — |
Eligibility Criteria
Inclusion Criteria
- Newly diagnosed or recurrent epidermoid cancer of the head and neck
- Requires more than minimal therapy for treatment
- Able to read and write in English
- Willing to use an effective form of birth control throughout the study
Exclusion Criteria
- Meets MINI criteria for major depression, schizophrenia, or bipolar illness or scores 24 or less
- Suicidal or psychotic
- Current allergy or hypersensitivity to citalopram or other SSRIs
- Treated with monoamine oxidase inhibitors 14 days prior to study entry
- Use of antidepressants within 1 week of study entry
- Pregnant or breastfeeding
- History of an adequate cancer operation, radiation, or chemotherapy within 6 months of study entry
- Diagnosed with melanoma or lymphoma cancer of the head and neck
- Currently participating in another research study involving a therapeutic intervention
Data sourced from ClinicalTrials.gov (NCT00536172). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.